11/21
08:17 am
sln
New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]
Medium
Report
New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]
11/20
01:19 pm
sln
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]
Medium
Report
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]
11/19
11:41 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.
11/18
02:33 pm
sln
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]
Medium
Report
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]
11/18
02:30 pm
sln
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Medium
Report
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
11/15
03:26 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/14
05:25 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
11/14
03:27 pm
sln
Silence Therapeutics reports Q3 results [Seeking Alpha]
Low
Report
Silence Therapeutics reports Q3 results [Seeking Alpha]
11/14
08:00 am
sln
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13
08:00 am
sln
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Medium
Report
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
10/28
01:12 pm
sln
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely [Yahoo! Finance]
10/22
05:36 pm
sln
Silence Therapeutics files for ordinary shares offering [Seeking Alpha]
Low
Report
Silence Therapeutics files for ordinary shares offering [Seeking Alpha]
10/8
12:57 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $49.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $49.00 price target on the stock.
9/11
06:08 pm
sln
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - Technavio
Low
Report
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - Technavio
9/8
09:56 am
sln
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]
Low
Report
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]
9/3
09:01 am
sln
Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
8/30
08:06 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
8/27
08:00 am
sln
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
Low
Report
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences